Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
0.2801
-0.0129 (-4.40%)
At close: May 11, 2026, 4:00 PM EDT
0.2900
+0.0099 (3.53%)
After-hours: May 11, 2026, 7:59 PM EDT
Soligenix Employees
As of December 31, 2025, Soligenix had 14 total employees, including 13 full-time and 1 part-time employees. The number of employees decreased by 2 or -12.50% compared to the previous year.
Employees
14
Change (1Y)
-2
Growth (1Y)
-12.50%
Revenue / Employee
n/a
Profits / Employee
-$782,434
Market Cap
2.89M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 14 | -2 | -12.50% | 13 | 1 |
| Dec 31, 2024 | 16 | 1 | 6.67% | 14 | 2 |
| Dec 31, 2023 | 15 | 0 | - | 13 | 2 |
| Dec 31, 2022 | 15 | 0 | - | 13 | 2 |
| Dec 31, 2021 | 15 | -3 | -16.67% | 13 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Valion Bio | 52 |
| Calidi Biotherapeutics | 29 |
| AIM ImmunoTech | 21 |
| Virax Biolabs Group | 19 |
| Decoy Therapeutics | 11 |
| Biodexa Pharmaceuticals | 11 |
| Ensysce Biosciences | 10 |
| Revelation Biosciences | 9 |
SNGX News
- 3 days ago - Soligenix reports Q1 EPS (28c) vs. (97c) last year - TheFly
- 3 days ago - Soligenix Announces Recent Updates and First Quarter 2026 Financial Results - PRNewsWire
- 7 days ago - Soligenix price target lowered to $1.50 from $10 at Alliance Global - TheFly
- 13 days ago - Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma - TheFly
- 13 days ago - Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire
- 5 weeks ago - Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial - TheFly
- 5 weeks ago - Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy - PRNewsWire
- 5 weeks ago - Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results - PRNewsWire